Endocrinology | Phase II Developments | UNITED STATES

Oramed Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CPhI Discover 2021

Participation Not Confirmed

Update your events

Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA’s Approved Dual Concurrent Protocol

Lead Product(s): Insulin

Therapeutic Area: Endocrinology Product Name: ORMD-0801

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 23, 2021

Details:

The double-blinded, placebo-controlled, multi-center randomized studies will recruit a total of 1,125 patients to evaluate the efficacy and safety of ORMD-0801.

Rezolute

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CPhI Discover 2021

Participation Not Confirmed

Update your events

Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021

Lead Product(s): RZ358

Therapeutic Area: Endocrinology Product Name: RZ358

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 22, 2021

Details:

The presentation, titled “Single and repeat-dose study of RZ358 in Patients with Post-Gastric Bypass Hypoglycemia: Results of Population PK/PD Modeling,” reported the results of a Phase 2a, single ascending and repeat dose study of IV RZ358 in 16 patients with PGBH.